Under the terms of the agreement, Genexine will use both the PharmaJet Stratis® and Tropis® devices in their Phase 1 and IIa human clinical studies. The agreement also includes provision for potential expansion to include Phase III studies and commercialization.
“We are pleased to be part of the upcoming clinical trials of these DNA vaccines. Our needle-free technology features a precise and consistent method of delivery, which helps to maximize target gene expression in the human body,” said Ron Lowy, chairman and chief executive officer, PharmaJet Inc. “In addition, it offers benefits over the alternative of electroporation delivery.”